Sherpa Healthcare Partners
CICC leads $60m Series B for China's Grit Biotechnology
CICC Capital had led a USD 60m Series B round for Grit Biotechnology, a Shanghai-based drug developer that is working on pioneering cancer treatments involving tumour-infiltrating lymphocytes (LIT).
China's Leadsynbio raises Series D
Chinese synthetic biology company Leadsynbio has raised a Series D round of unspecified size from existing investors Lilly Asia Ventures and Sherpa Healthcare Partners.
China cell therapy developer Neukio raises $50m
Shanghai-based cell therapy developer Neukio Biotherapeutics has raised USD 50m in the first tranche of a Series A round led by medical technology-focused CD Capital. Other new investors include Alwin Capital and Surplus Capital.
Legend leads $150m Series E for China CRO ClinChoice
US and China-based clinical contract research organization (CRO) company ClinChoice has raised a USD 150m Series E round led by Legend Capital.
China RNA vaccine developer raises $42m
Therorna, a China-based biotech company specializing in vaccines and drugs based on circular RNA technology, has raised USD 42m in Series A funding.
Sequoia China leads $100m Series B for Bota Biosciences
Sequoia Capital China had led a $100 million Series B round for Bota Biosciences, a China-based biotech company that has developed a next-generation platform for manufacturing high-performing industrial compounds.
Sherpa Healthcare leads Series A for Paq Therapeutics
Sherpa Healthcare Partners has led a $30 million Series A for Paq Therapeutics, a Chinese-founded biotech company specializing in treatments based on molecules that enhance the degradation of disease-causing entities.
Loyal Valley leads Series B extension for China's Edigene
Loyal Valley Capital has led a RMB400 million ($62 million) Series B extension for EdiGene, a China-based biotech company that uses genome editing technologies to accelerate drug discovery.